General
12 articles in the General category
Membranolytic Peptides Trigger Immunogenic Cell Death in Cancer Treatment
Researchers report that membranolytic peptides can program immunogenic cell death, offering a novel approach to cancer therapy. The strategy leverages the peptides' membrane-disrupting properties to induce a form of cell death that activates an immune response. This finding, published by Nature, highlights a potential new avenue for cancer treatment.
5 min readPeptide Therapy for Erectile Dysfunction: Overview and Insights
This article provides an overview of peptide therapy as a potential approach for erectile dysfunction, referencing a specific report titled 'Peptide Therapy for Erectile Dysfunction - View E8bbJ0QKa' from FC Bayern. The report was published on August 2, 2026, and is categorized under General. The article summarizes the key points and context surrounding this topic.
5 min readBPC-157 News: FDA Advisers Weigh Easing Restrictions on Six Peptides
FDA advisers have reportedly supported easing restrictions on six peptides, a move that could reshape the peptide research landscape. While BPC-157 and TB-500 were not explicitly named, the decision signals growing regulatory attention. Here's what researchers and industry professionals should know.
5 min readOrforglipron vs. Tirzepatide: Major Differences in Semaglutide News
This analysis compares orforglipron and tirzepatide, two emerging compounds in the GLP-1 receptor agonist space, against the backdrop of recent semaglutide news. We explore their mechanisms, research status, and potential implications for peptide researchers and industry professionals.
5 min readSamsung Biologics Acquires PolyPeptide: Semaglutide News and Industry Impact
Samsung Biologics has proposed a $1.8 billion acquisition of Swiss CDMO PolyPeptide, signaling major growth in peptide manufacturing. This semaglutide news highlights the expanding role of contract development and manufacturing organizations in meeting rising demand for GLP-1 receptor agonists like semaglutide.
4 min readCompounders News: How Compounding Pharmacies Maintain GLP-1 Market Grip
Compounding pharmacies continue to hold a strong position in the GLP-1 market, according to recent industry analysis. This article examines the factors behind their sustained influence and what it means for peptide researchers and industry professionals.
3 min readWhat Older Adults Should Know About GLP: Semaglutide News and Pancreatic Cancer Research
Recent developments in peptide research include a novel approach to pancreatic cancer treatment announced by Neo7Bioscience. This article explores what older adults should know about GLP-related therapies, including semaglutide news, and how precision signal interception may offer new hope beyond conventional RAS pathway suppression.
4 min readSemaglutide News: Ozempic Linked to Fewer Bone Fractures Despite Greater Weight Loss
Recent data presented at the American Diabetes Association annual meeting suggests semaglutide (Ozempic, Wegovy) may reduce bone fracture risk even with significant weight loss. This semaglutide news adds a new dimension to GLP-1 research, with implications for metabolic and skeletal health.
4 min read
Brain-Protecting Peptide Discovery May Shift Parkinson’s Treatment
Scientists have identified a peptide that protects brain cells, potentially altering how Parkinson’s disease is treated. The discovery, reported by SciTechDaily on June 17, 2026, highlights a new avenue for slowing neurodegeneration. The peptide’s protective effects could lead to therapies that target the underlying causes of Parkinson’s rather than just symptoms.
2 min read
Functional Peptide Screening Advances for GPCRs and Radiopharma
Pharmaceutical companies show increased focus on G protein-coupled receptors and radioligand therapies, highlighting functional peptide screening platforms. Eli Lilly paid $140 million upfront to Radionetics Oncology in July 2024 for access to novel GPCR targets, with an option to acquire for $1 billion. These platforms help identify agonists that activate signaling pathways, setting them apart in drug discovery.
3 min readPrecision Peptide CSO Justin Kirkland on Human Upgrade with Dave Asprey
Justin Kirkland serves as Chief Scientific Officer at The Precision Peptide Company. He will be featured on The Human Upgrade with Dave Asprey. This guest appearance places the company executive on the show hosted by Dave Asprey. Kirkland's role leads to this program feature.
2 min readLüt Partners with APA and AIVA for Compliant Peptide Payments
Lüt has announced a partnership with the American Peptide Association (APA) and American IV Association (AIVA). The collaboration aims to provide compliant payments for the peptide and wellness industries. This news comes from Business Wire on 2026-05-05.
1 min readOther categories